Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | NEK2 | P51955 | 1/20 | 0.39 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | RPA1 | P27694 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9105334 | 0.90 | CHEK1 (0.39) | CHEK1AURKACSNK1A1CDK8NEK2 | |
| SCHEMBL4943018 | 0.90 | CHEK1 (0.39) | CHEK1AURKACSNK1A1CDK8NEK2 | |
| SCHEMBL9108371 | 0.88 | — | — | |
| SCHEMBL15313204 | 0.81 | VCAM1 (0.36) | MEN1KMT2APKMSMN1; SMN2 | |
| SCHEMBL9108861 | 0.78 | — | — | |
| SCHEMBL2720819 | 0.72 | CHEK1 (0.42) | MEN1KMT2ACHEK1AURKACSNK1A1 | |
| SCHEMBL9108850 | 0.71 | — | — | |
| SCHEMBL2724848 | 0.71 | KDM1A (0.32) | — | |
| SCHEMBL15312915 | 0.68 | — | — | |
| SCHEMBL4942592 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447080-B2 | Viral polymerase inhibitors | BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) | 2016-09-20 | — | — | US | disclosed |
| US-9120775-B2 | Viral polymerase inhibitors | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2015-09-01 | — | — | US | disclosed |
| US-20150065445-A1 | Viral Polymerase Inhibitors | BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) | 2015-03-05 | — | — | US | disclosed |
| WO-2013152391-A1 | VIRAL POLYMERASE INHIBITORS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-10-17 | — | — | WO | disclosed |
| US-20130274218-A1 | VIRAL POLYMERASE INHIBITORS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065445-A1 | Viral Polymerase Inhibitors | POLR2E, POLM, POLR2H | MEN1 4869/4885KMT2A 4465/4885CHEK1 3417/4885 |
| US-20130274218-A1 | VIRAL POLYMERASE INHIBITORS | POLR2E, POLM, POLR2H | MEN1 4869/4885KMT2A 4465/4885CHEK1 3417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.